Acer Therapeutics Overview
- Status
-
Public
- Employees
-
39
- Stock Symbol
-
ACER
- Investments
-
2
- Share Price
-
$0.66
- (As of Monday Closing)
Acer Therapeutics General Information
Description
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
PINX
Primary Office
- One Gateway Center, 300 Washington Street
- Suite 356
- Newton, MA 02458
- United States
+1 (844) 000-0000
Acer Therapeutics Timeline
Acer Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.66 | $0.80 | $0.55 - $4.56 | $16.1M | 24.5M | 2.39M | -$2.22 |
Acer Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 50,656 | 50,846 | 18,476 | 26,029 |
| Revenue | 372 | 0 | 1,260 | 0 |
| EBITDA | (47,397) | (26,070) | (15,823) | (22,828) |
| Net Income | (48,487) | (26,237) | (15,374) | (22,885) |
| Total Assets | 14,002 | 11,624 | 36,257 | 14,614 |
| Total Debt | 47,534 | 11,864 | 394 | 364 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Acer Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Acer Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Acer Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development,
Drug Discovery
Newton, MA
39
As of 2023
000.00
000
0000-00-00
000000&0
000.00
000000
olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
000000000000000
Lexington, MA
000
As of 0000
00000
0.000
0000-00-00
000000&0
00000
000000
etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
000000000000000
Wilmington, DE
0000
As of 0000
00000000000
Add Comparison
Acer Therapeutics Competitors (97)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | 000 | 00000 | 000000&0 | 00000 |
| 000000 | Formerly VC-backed | Wilmington, DE | 0000 | 00000000000 | ||
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 0000000000 | |
| 00000000 000000000 | Formerly VC-backed | Pratteln, Switzerland | 00 | 00000 | 000000000 | 00000 |
Acer Therapeutics Patents
Acer Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220177469-A1 | Solid forms of emetine | Pending | 04-Dec-2020 | 0000000000 | 0 |
| EP-4255431-A1 | Solid forms of emetine | Pending | 04-Dec-2020 | 0000000000 | |
| CA-3189841-A1 | Nk receptor antagonists for cancer patients | Pending | 30-Jul-2020 | 00000000000 | |
| AU-2021315801-A1 | Nk receptor antagonists for cancer patients | Pending | 30-Jul-2020 | 00000000000 | |
| US-20230277518-A1 | Nk receptor antagonists for cancer patients | Pending | 30-Jul-2020 | A61K31/4545 |
Acer Therapeutics Executive Team (16)
Acer Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chris Schelling | Acer Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| Jason Amello | Self | Board Member | 000 0000 |
| John Dunn JD | Acer Therapeutics | Board Member | 000 0000 |
| Michelle Griffin | Self | Board Member | 000 0000 |
| Stephen Aselage | Self | Chairman | 000 0000 |
Acer Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Acer Therapeutics Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Opexa Therapeutics | 19-Sep-2017 | 0000000000 | 00.000 | Biotechnology | 00000 000 |
| Anchor Therapeutics | 20-Mar-2015 | Merger/Acquisition | Drug Discovery |
Acer Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Acer Therapeutics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Anchor Therapeutics | 20-Mar-2015 | 000000000000000000 | Completed |
|